Market News & Trends
Ocugen On Track to Submit EUA Application to US FDA for its COVID-19 Vaccine Candidate
Ocugen, Inc. recently confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the US FDA in June. “Since we have…
EXECUTIVE INTERVIEW - Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
Microfluidics: An Alternative Method for Developing Nanoparticle Drug Delivery Systems
The encapsulation of drugs within purposely formulated liposome nanoparticles offers the potential for more controlled and sustained release, as well as reducing toxicity and….
Stevanato Group & Corning Incorporated Sign Licensing Agreement to Offer Corning Valor Glass Vials in Presterilized SG EZ-fill Packaging Configuration
Stevanato Group recently announced a licensing agreement with Corning Incorporated to offer a combined solution that will provide biopharmaceutical companies with improved levels of….
Evonik Markets New Enteric-Protected Ready-to-Fill Capsules for Fast, High-Performance Drug Development
Evonik recently launched the EUDRACAP platform of easy-to-handle capsules to help the pharmaceutical industry accelerate speed to market for complex oral drug products in early development stages…..
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
Myriad Genetics, Inc. recently announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization….
Ginkgo Bioworks & Biogen Announce Collaboration & License Agreement to Develop Novel Gene Therapy Manufacturing Platform
Ginkgo Bioworks and Biogen recently announced a gene therapy collaboration in which the companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors…..
Xalud Therapeutics’ Lead Candidate Achieves Multiple Clinical Milestones in Pathologic Inflammation & Neuroimmunology Therapeutic Areas
Xalud Therapeutics recently announced that the Phase 2b study of XT-150 in patients with moderate-to-severe pain due to osteoarthritis (OA) of the knee has completed…
VBL Therapeutics to Provide Update on OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
VBL Therapeutics recently announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will…
Onconova Therapeutics Announces Initial Dosing of First Patient in US Phase 1 Clinical Trial
Onconova Therapeutics, Inc. recently announced the first patient has been dosed in the US Phase 1 clinical trial of ON 123300, the company’s proprietary, novel…
The Discovery Labs Signs Foundational Lease With the University of Pennsylvania Gene Therapy Program as Anchor Tenant
The Discovery Labs has recently signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus…
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 Neutralizing Antibody CTL-002
CatalYm GmbH recently announced that their abstract with first interim data from the Phase 1 clinical trial investigation CTL-002 as monotherapy and in combination with…
Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity With New Multi-Purpose Fill Suite
Ajinomoto Bio-Pharma Services recently announced it will soon open a high-speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego,…
Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation & Sustainability in Digital Drug Delivery
Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic, and MedTech devices, recently unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation, and sustainability in the digital drug-delivery device market….
Biogen & Envisagenics Announce Collaboration to Advance RNA Splicing Research
Biogen Inc. and Envisagenics recently announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases….
Mustang Bio & City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial
Mustang Bio, Inc. and City of Hope recently announced the first patient has been dosed in a clinical trial to establish the safety and feasibility…
Calithera Biosciences & Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
Calithera Biosciences, Inc. and Antengene Corporation, Ltd. recently announced an exclusive, worldwide license agreement for the development and commercialization of CB-708, Calithera’s small….
Agenus & Bristol Myers Squibb Announce Exclusive Global License for Anti-TIGIT Bispecific Antibody Program
Bristol-Myers Squibb Company and Agenus Inc. recently announced they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to….
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients With Pre-existing Antibodies to AAV5 Vector
uniQure N.V. recently presented 26-week clinical data from the pivotal, Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients…
Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate
Ocuphire Pharma, Inc. recently announced the United States Patent and Trademark Office (USPTO) has issued two patents covering the company’s late-stage product candidate, Nyxol (phentolamine…
